Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 110

Sort by

Sort Order Select

Journal Articles

Marrow Hypercellularity Does Not Exclude the Diagnosis of Essential Thrombocythemia (ET)

Katie Erdos, Madhu M Ouseph, Julia Geyer, Neville Lee, Jr., Ghaith Abu-Zeinah, Joseph M. Scandura, Richard T. Silver

Blood (2023) 142 (Supplement 1): 3198.

https://doi.org/10.1182/blood-2023-187769

Published: 2023

Journal Articles

Importance of Diagnosing Polycythemia Vera (PV) Patients (pts) Whose Hematocrit (HCT)/Hemoglobin (HGB) Are Less Than the Who 2022 Stipulated Criteria

Neville Lee, Jr., Katie Erdos, Joseph M. Scandura, Ghaith Abu-Zeinah, Richard T. Silver

Blood (2023) 142 (Supplement 1): 6434.

https://doi.org/10.1182/blood-2023-189643

Published: 2023

Journal Articles

Low Thrombosis Risk CALR Mutations Confer Higher Risk of Essential Thrombocythemia Progression

Katie Erdos, Neville Lee, Jr., Ahamed Lebbe, Imane Bouhali, Mohammed Khalid, Ghaith Abu-Zeinah, Richard T. Silver, Joseph M. Scandura

Blood (2023) 142 (Supplement 1): 1819.

https://doi.org/10.1182/blood-2023-188952

Published: 2023

Journal Articles

Impact of Graft Source [Cord Blood Supported By CD34+ Selected Cells (Haplo-Cord) Vs. Matched Donor] on Transplant Outcomes in Myelofibrosis

Nima Ghalehsari, Zhengming Chen, Sebastian A. Mayer, Ghaith Abu-Zeinah, Tsiporah B. Shore, Ellen K. Ritchie, Richard T. Silver, Andrew I. Schafer, Joseph M. Scandura, Gail J. Roboz, Koen Van Besien, Alexandra Gomez-Arteaga

Blood (2023) 142 (Supplement 1): 6953.

https://doi.org/10.1182/blood-2023-185075

Published: 2023

Journal Articles

Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV

Ghaith Abu-Zeinah, Spencer Krichevsky, Katie Erdos, Richard T. Silver, Joseph Scandura

Blood (2022) 140 (Supplement 1): 3961–3962.

https://doi.org/10.1182/blood-2022-170893

Published: 2022

Journal Articles

Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2 V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival

Ghaith Abu-Zeinah, Franco Castillo Tokumori, Katie Erdos, Imane Bouhali, Daniel C Choi, Richard T. Silver, Joseph Scandura

Blood (2022) 140 (Supplement 1): 6819–6820.

https://doi.org/10.1182/blood-2022-168283

Published: 2022

Journal Articles

Safety of Cytoreductive Therapy in Younger Patients with Polycythemia Vera: A Systematic Review and Meta-Analysis

Reem S. Chamseddine, Shehroz Rana, Mohammed Khalid, Nicole Kucine, Richard T. Silver, Joseph Scandura, Ghaith Abu-Zeinah

Blood (2022) 140 (Supplement 1): 3999–4000.

https://doi.org/10.1182/blood-2022-168014

Published: 2022

Journal Articles

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood (2022) 139 (19): 2931–2941.

https://doi.org/10.1182/blood.2021012743

Published: 2022

Includes: Supplemental data

Journal Articles

Splenomegaly (SPML) in Polycythemia Vera (PV): Its Clinical Significance and Relation to Myelofibrosis and Survival

Richard T. Silver, Elwood Taylor, III, Joseph Scandura, Ghaith Abu-Zeinah

Blood (2021) 138 (Supplement 1): 2580.

https://doi.org/10.1182/blood-2021-149137

Published: 2021

Journal Articles

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Blood (2021) 138 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2021-150561

Published: 2021

Journal Articles

Normal Life Expectancy for Polycythemia Vera Patients Is Possible

Ghaith Abu-Zeinah, Richard T. Silver, Khalid Abu-Zeinah, Joseph Scandura

Blood (2021) 138 (Supplement 1): 2575.

https://doi.org/10.1182/blood-2021-147061

Published: 2021

Journal Articles

A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients

Ghaith Abu-Zeinah, Spencer Krichevsky, Richard T. Silver, Elwood Taylor, III, Douglas Tremblay, Andrew Srisuwananukorn, John Mascarenhas, Joseph Scandura

Blood (2021) 138 (Supplement 1): 3619.

https://doi.org/10.1182/blood-2021-149098

Published: 2021

Journal Articles

Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for JAK2 V617F Myeloproliferative Neoplasms (MPNs)

Ghaith Abu-Zeinah, Silvana Di Giandomenico, Tatiana Cruz, Daniel Choi, Elwood Taylor, III, Ellen Ritchie, Richard T. Silver, Joseph Scandura

Blood (2021) 138 (Supplement 1): 627.

https://doi.org/10.1182/blood-2021-153003

Published: 2021

Journal Articles

Excess Mortality in Young Patients with Myeloproliferative Neoplasms

Khalid Abu-Zeinah, Khalil Saadeh, Richard T. Silver, Joseph Scandura, Ghaith Abu-Zeinah

Blood (2021) 138 (Supplement 1): 235.

https://doi.org/10.1182/blood-2021-146029

Published: 2021

Journal Articles

Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials

Gina L. Mazza, PhD, Carolyn Mead-Harvey, MS, John Mascarenhas, MD, Abdulraheem Yacoub, MD, Ronald Hoffman, MD, Heidi E. Kosiorek, MS, Josef T. Prchal, MD, Richard T. Silver, MD, Tiziano Barbui, MD, Amylou C. Dueck, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-142817

Published: 2020

Journal Articles

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Ghaith Abu-Zeinah, MD, Spencer Krichevsky, BS, Tatiana Cruz, MD, Gabriela Hoberman, BA, Niamh Savage, BA, Ellen Ritchie, MD, Joseph Scandura, MDPhD, Richard T. Silver, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141796

Published: 2020

Journal Articles

Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3

Nicole Mollé, Spencer Krichevsky, Pouneh Kermani, Richard T. Silver, Ellen Ritchie, Joseph M. Scandura

Blood (2020) 135 (13): 1062–1066.

https://doi.org/10.1182/blood.2019003050

Published: 2020

Includes: Supplemental data

Journal Articles

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Spencer Krichevsky, BS, Ghaith Abu Zeinah, MD, Claudia Sosner, BA, Diana Jaber, BA, Niamh Savage, BA, Gabriela Hoberman, BA, Ellen K. Ritchie, MD, Andrew I. Schafer, MD, Richard T. Silver, MD, Joseph Scandura, MD PhD

Blood (2019) 134 (Supplement_1): 1664.

https://doi.org/10.1182/blood-2019-131605

Published: 2019

Journal Articles

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Shien Guo, PhD, Weiqin Liao, MS, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 2207.

https://doi.org/10.1182/blood-2019-129386

Published: 2019

Journal Articles

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Ghaith Abu Zeinah, MD, Spencer Krichevsky, BS, Diana Jaber, BA, Niamh Savage, BA, Claudia Sosner, BA, Gabriela Hoberman, BA, Ellen K. Ritchie, MD, Andrew I. Schafer, MD, Joseph Scandura, MD PhD, Richard T. Silver, MD

Blood (2019) 134 (Supplement_1): 2942.

https://doi.org/10.1182/blood-2019-130265

Published: 2019

NARROW

Marrow Hypercellularity Does Not Exclude the Diagnosis of Essential Thrombocythemia (ET)

Importance of Diagnosing Polycythemia Vera (PV) Patients (pts) Whose Hematocrit (HCT)/Hemoglobin (HGB) Are Less Than the Who 2022 Stipulated Criteria

Low Thrombosis Risk CALR Mutations Confer Higher Risk of Essential Thrombocythemia Progression

Impact of Graft Source [Cord Blood Supported By CD34+ Selected Cells (Haplo-Cord) Vs. Matched Donor] on Transplant Outcomes in Myelofibrosis

Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV

Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2 V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival

Safety of Cytoreductive Therapy in Younger Patients with Polycythemia Vera: A Systematic Review and Meta-Analysis

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Splenomegaly (SPML) in Polycythemia Vera (PV): Its Clinical Significance and Relation to Myelofibrosis and Survival

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Normal Life Expectancy for Polycythemia Vera Patients Is Possible

A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients

Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for JAK2 V617F Myeloproliferative Neoplasms (MPNs)

Excess Mortality in Young Patients with Myeloproliferative Neoplasms

Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only